PRXL
PAREXEL Intl Corp.
Set alert
- Open
- 88.10
- Prev close
- 88.08
- Mkt cap
- 4.50B
- Vol
- 7.02M
- Avg vol
- 828.03K
- EPS
- 2.06
- P/E
- 42.76
- Div yield
- 0.00%
More statistics
- Low
- 88.07
- High
- 88.10
- Forward P/E
- 19.70
- Beta
- 0.70
- Short ratio
- 0.57
- Inst. own
- 90.14%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 88.02
- 200-d avg
- 82.58
- 1y target
- 88.70
Key statistics
- Market cap
- 4.50B
- Enterprise value
- 4.87B
- Trailing P/E
- 42.76
- Forward P/E
- 19.70
- PEG ratio
- 0.00
- Price / sales
- 2.13
- Price / book
- 7.09
- EPS (TTM)
- 2.06
- Beta
- 0.70
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 5.07%
- Revenue (TTM)
- 2.12B
- Revenue growth
- 3.80%
- Free cash flow
- 247.82M
- Total cash
- 302.70M
- Total debt
- 671.50M
- Return on equity
- 16.93%
- Shares outstanding
- 51.12M
- Short % of float
- 0.97%
- 50-day average
- 88.02
- 200-day average
- 82.58
Analyst view
Consensus: hold
- Target (low)
- 88.00
- Target (mean)
- 88.70
- Target (high)
- 90.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 8, 2017 | Mar 31, 2017 | — | 0.34 | — | — |
| Feb 8, 2017 | Dec 31, 2016 | — | 0.42 | — | — |
| Nov 14, 2016 | Sep 30, 2016 | — | 0.71 | — | — |
| Sep 29, 2016 | Jun 30, 2017 | — | 0.58 | — | — |
| Feb 2, 2016 | Dec 31, 2015 | — | 0.73 | — | — |
| Sep 29, 2015 | Jun 30, 2016 | — | 0.80 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 22, 2017 | Goldman Sachs | up | — | Neutral |
| May 14, 2017 | Evercore ISI Group | up | — | Outperform |
| Feb 5, 2017 | Credit Suisse | down | — | Neutral |
| Feb 2, 2017 | Citigroup | down | — | Neutral |
| Feb 2, 2017 | Deutsche Bank | down | — | Sell |
| Jan 3, 2017 | Evercore ISI Group | down | — | Hold |
About PAREXEL Intl Corp.
PAREXEL International Corporation, a biopharmaceutical outsourcing services company, provides clinical research and logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting Services (PC), and PAREXEL Informatics (PI). The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management, and biostatistical analysis, epidemiology and health economics/outcomes research, clinical supply and drug logistics, pharmacovigilance, commercialization, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. The PC segment provides technical expertise and advice in various areas, such as drug development, regulatory affairs, product pricing and reimbursement, commercialization, and strategic compliance; and market and product development, and targeted communications services to support product launch, as well as offers solutions to address client issues associated with product development, registration, and commercialization. The PI segment provides information technology solutions comprising ClinPhone randomization and trial supply management solutions, medical imaging services, IMPACT clinical trial management systems, LIQUENT InSight regulatory information management software and professional services, DataLabs electronic data capture systems, Web-based portals, systems integration services, electronic patient reported outcomes, and patient diary applications, as well as centralized assessment services for patient technology solutions. PAREXEL International Corporation was founded in 1983 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Laboratories & Research
- Country
- United States
- Website
- parexel.com
News
- Real World Evidence (RWE) Oncology Market to Reach $3.51 Billion by 2035, Growing at a CAGR of 14.7% from 2025--Exclusive Report by Meticulous Research®
- Parexel International Announces Date of Third Quarter Fiscal Year 2017 Earnings Release and Conference Call
- PAREXEL International Announces Date of Second Quarter Fiscal Year 2017 Earnings Release and Conference Call
- PAREXEL International Announces Date of First Quarter Fiscal Year 2017 Earnings Release and Conference Call
- PAREXEL International Announces Date of Fourth Quarter and Fiscal Year 2016 Earnings Release and Conference Call
- PAREXEL International Announces Date of Third Quarter Fiscal Year 2016 Earnings Release and Conference Call
- PAREXEL International Announces Date of Second Quarter Fiscal Year 2016 Earnings Release and Conference Call
- PAREXEL International Announces Date of First Quarter Fiscal Year 2016 Earnings Release and Conference Call
- Don't Forget About This Small-Cap Health Care ETF
Your note
Sign in to keep a note on PRXL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERSSON ROLAND | Officer | Disposition (Non Open Market) | Sep 28, 2017 | 0 |
| BANK INGO | Officer | Disposition (Non Open Market) | Jul 7, 2016 | 21,245 |
| BATT DOUGLAS A | Officer | Disposition (Non Open Market) | Sep 28, 2017 | 0 |
| CALLOW A DANA JR | Director | Disposition (Non Open Market) | Sep 28, 2017 | 0 |
| FLINOIS XAVIER | Officer | Disposition (Non Open Market) | Sep 28, 2017 | 0 |
| FORTUNE PATRICK J | Director | Disposition (Non Open Market) | Sep 28, 2017 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.63% | 5,432,566 | 472.69M | Jun 29, 2017 |
| Vanguard Group, Inc. (The) | 8.23% | 4,205,566 | 365.93M | Jun 29, 2017 |
| Fisher Asset Management, LLC | 4.14% | 2,114,547 | 183.99M | Jun 29, 2017 |
| State Street Corporation | 3.41% | 1,744,373 | 151.78M | Jun 29, 2017 |
| Alpine Associates Management Inc. | 2.56% | 1,308,435 | 113.85M | Jun 29, 2017 |
| CNH Partners LLC | 2.47% | 1,265,075 | 110.07M | Jun 29, 2017 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Core S&P Midcap ETF | 2.38% | 1,215,080 | 105.72M | Jun 29, 2017 |
| Vanguard Small-Cap Index Fund | 2.33% | 1,190,585 | 74.65M | Mar 30, 2017 |
| Vanguard Total Stock Market Index Fund | 2.22% | 1,132,596 | 71.01M | Mar 30, 2017 |
| Vanguard Specialized-Health Care Fund | 2.17% | 1,108,785 | 70.26M | Apr 29, 2017 |
| iShares Russell 2000 ETF | 1.91% | 974,288 | 84.77M | Jun 29, 2017 |
| Vanguard Small-Cap Growth Index Fund | 1.27% | 651,301 | 40.84M | Mar 30, 2017 |